V
Ventus Therapeutics
Applying structural immunology to discover and develop therapeutics targeting immune pathways to address human disease
About Ventus Therapeutics
Ventus Therapeutics is a clinical-stage biopharmaceutical startup that operates in the healthcare sector, specifically in the fields of immunology, inflammation, and neurology. The company is currently working on developing a pipeline of innovative medicines, with its most advanced program, VENT-02, being a brain-penetrant NLRP3 inhibitor currently in Phase 1. In simpler terms, this means that the company is in the early stages of testing a new drug that can penetrate the brain and inhibit a protein involved in inflammation and immune response.
The company's business model revolves around the research, development, and eventual commercialization of these novel medicines. Their primary clients are likely to be healthcare providers and patients suffering from conditions related to immunology, inflammation, and neurology. The company generates revenue through the successful development and sale of its pharmaceutical products.
Ventus Therapeutics places a strong emphasis on its team, believing in the power of innovative solutions to solve complex problems. They are continually seeking talented individuals to join their team and contribute to their scientific pursuits.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Montreal, Canada
- Employees
- 56
- Open positions
- None listed
- Dealroom signal
- 28.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Apr 2023 | $150K | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
| LATE VCOther financing | Sep 2022 | $70M | $280M | Novo Nordisk | ↗ |
Growth signals
Latest recorded traffic for Ventus Therapeutics is 7.5K monthly website visits, up 19% over the last three months. Ventus Therapeutics's team declined 23.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Michael J. Fox Foundation for Parkinson's Research
Series A7 investors entered at this stage
Versant Ventures
RA Capital Management
Alexandria Venture Investments
Casdin Capital
BVF Partners
Fonds de solidarité FTQ
Cormorant Asset Management
Series B and later5 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ventus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ventus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.